Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Challenge to Thai Drug Licensing (Thailand)

This article was originally published in PharmAsia News

Executive Summary

Emcure Pharmaceuticals is being threatened with legal action by the Sanofi-Aventis, patent holder of the cardiac drug Plavix. Emcure secured an order from the Thai government to produce clopidogrel, the generic version of Plavix. In a notice to Bioscience Co. Ltd, the agent of Emcure in Thailand, Sanofi-Aventis said that any unauthorized importation, manufacture, and sale of the generic clopidogrel will infringe Sanofi's patent rights of clopidogrel under Thai law. Sanofi says that in the event of infringement of its patent, the company "will be entitled to sue the company in a civil action for compensation. Emcure says it has received assurances of support from the Thai government. (Click here for more
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC066562

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel